MAP Pharmaceuticals will seek federal approval for its migraine treatment candidate in the first half of next year, the company said Tuesday.
Levadex, which is inhaled, is in late-stage clinical testing. The drugmaker said it has completed enrollment in a trial evaluating safety for patients receiving six or 12 months of treatment........................&more
No comments:
Post a Comment